https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54430 Tue 27 Feb 2024 13:58:29 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48331 75% for each characteristic) would not modify duration based on host characteristics such as patient age or co-morbidities. ID physicians recommended longer durations than ICU physicians for all five syndromes (ID, median 10, IQR 7–14, range 1–28 days; ICU, median 7, IQR 5–10, range 2–21 days). Across all respondents, the median (IQR) duration for each syndrome was: CVC-BSI, 7 (7–10) days; bacteraemic pneumonia, 7 (7–10) days; bacteraemic UTI, 10 (7–14) days; bacteraemic IAI, 7 (7–12) days; and bacteraemic SSTI, 10 (7–14) days. Marked variation exists amongst clinicians’ recommended duration of antibiotic treatment for BSI. A proportion of clinicians recommend therapy of ≤7 days at present (33.3–59.7% across scenarios). Patient characteristics are not strongly considered in the decision on therapy duration. This survey was undertaken as preparatory work for initiation of the BALANCE study, an ongoing randomised trial comparing 7 days with 14 days of therapy for BSI, providing an evidence base to inform best clinical treatment for this patient population.]]> Tue 14 Mar 2023 16:54:42 AEDT ]]>